الإحصائيات الأساسية
| LEI | 549300BRZWG25RBYA369 |
| CIK | 1457612 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genocea Biosciences Inc
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-36289 Commission File Number GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified i |
|
| June 9, 2022 |
As filed with the Securities and Exchange Commission on June 9, 2022 As filed with the Securities and Exchange Commission on June 9, 2022 Registration No. |
|
| June 9, 2022 |
As filed with the Securities and Exchange Commission on June 9, 2022 As filed with the Securities and Exchange Commission on June 9, 2022 Registration No. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 POS 1 a2014initials-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333-194021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-194021 UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its cha |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 POS 1 a2020incrementals-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333-238878 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-238878 UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 POS 1 a2021evergreens-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333-253364 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-253364 UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its c |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 POS 1 a2017evergreens-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333-216183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-216183 UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its c |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 POS 1 a2022evergreens-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333-263699 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-263699 UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its c |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 POS 1 a2015evergreens-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333-202333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-202333 UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its c |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 S-8 POS 1 a2014espps-8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. 333-197127 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-197127 UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charte |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36289 GENOCEA BIOSCIENCES, INC. THE NASDAQ CAPITAL MARKET (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 10 |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| May 27, 2022 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842 |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 GENOCEA BIOSCIENCES, INC. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36289 GENOCE |
|
| April 29, 2022 |
Exhibit 10.30 September 12, 2016 Dear Jess: This letter (the "Amendment") amends the letter agreement between you and Genocea Biosciences, Inc. (the "Company"), dated January 16, 2014 (the "Employment Agreement"), effective as of the date hereof. All capitalized terms used in this Amendment shall have the meanings ascribed to them in the Employment Agreement unless otherwise expressly provided her |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| April 28, 2022 |
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives Investor Contact: Media Contact: Dan Ferry Sarah O?Connell daniel@lifesciadvisors. |
|
| March 18, 2022 |
Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Genocea Biosciences Inc. (?Genocea,? ?we,? ?our,? or ?us?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.001 par value per share. DESCRIPTION OF CAPITAL STOCK The |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36289 GENOCEA BIOSCIENCES, INC. |
|
| March 18, 2022 |
Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) GENOCEA BIOSCIENCES, INC. |
|
| March 18, 2022 |
As filed with the Securities and Exchange Commission on March 18, 2022 As filed with the Securities and Exchange Commission on March 18, 2022 Registration No. |
|
| March 18, 2022 |
Exhibit 10.28 Portions of this exhibit have been redacted because they are both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark [* * *]. COLLABORATION & OPTION AGREEMENT This Collaboration & Option Agreement (?Agreement?) is dated December 28, 2021, (the ?Effe |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| March 10, 2022 |
Investor Contact: Media Contact: Dan Ferry Sarah O?Connell daniel@lifesciadvisors. |
|
| March 7, 2022 |
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors CAMBRIDGE, Mass. |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2022 |
GNCA / Genocea Biosciences Inc / COMMODORE CAPITAL LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427401 (CUSIP Number) December |
|
| February 14, 2022 |
GNCA / Genocea Biosciences Inc / CITADEL ADVISORS LLC - GENOCEA BIOSCIENCES, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* Genocea Biosciences Inc (Name of Issuer) Common Stock, $0.001 par value per share (the ?Shares?) (Title of Class of Securities) 372427401 ( |
|
| February 10, 2022 |
GNCA / Genocea Biosciences Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| January 4, 2022 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Media Contact: Sarah O’Connell [email protected] Genocea Biosciences Provides Corporate Update Enters into Inhibigen™ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN™ trial CAMBRIDGE, Mass., January 4, 2022 - Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commiss |
|
| October 28, 2021 |
Investor Contact: Media Contact: Dan Ferry Sarah O?Connell daniel@lifesciadvisors. |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 GENOCEA BIOSCIENCES, INC. |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| September 13, 2021 |
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors Investor Contact: Media Contact: Dan Ferry Sarah O?Connell daniel@lifesciadvisors. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 GENOCEA BIOSCIENCES, INC. |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 29, 2021 |
Investor Contact: Media Contact: Dan Ferry Sarah O?Connell daniel@lifesciadvisors. |
|
| July 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 13, 2021 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Media Contact: Sarah O?Connell [email protected] Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy CAMBRIDGE, Mass., July 13, 2021 - Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, to |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| June 24, 2021 |
Exhibit 3.1 GENOCEA BIOSCIENCES, INC. Restated Certificate of Incorporation Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware, Genocea Biosciences, Inc. has adopted this Restated Certificate of Incorporation restating, integrating and further amending its Amended and Restated Certificate of Incorporation (originally filed on August 16, 2006, under the name ?G |
|
| June 4, 2021 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Media Contact: Sarah O?Connell [email protected] Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021 Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 v |
|
| June 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2021 |
$35,808,111 GENOCEA BIOSCIENCES, INC. Common Stock 424B5 1 prospectussupplementatm.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-255610 PROSPECTUS SUPPLEMENT (To Prospectus dated May 10, 2021) $35,808,111 GENOCEA BIOSCIENCES, INC. Common Stock We have entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen"), relating to shares of our common stock offered by this prospectus supplement. In accord |
|
| May 10, 2021 |
$23,972,805 GENOCEA BIOSCIENCES, INC. Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-255610 PROSPECTUS SUPPLEMENT (To Prospectus dated May 10, 2021) $23,972,805 GENOCEA BIOSCIENCES, INC. Common Stock We have entered into a purchase agreement (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park") on October 23, 2019, relating to shares of our common stock offered by this prospectus supplement. In accorda |
|
| May 6, 2021 |
GENOCEA BIOSCIENCES, INC. 100 Acorn Park Drive Cambridge, Massachusetts 02149 (617) 876-8191 GENOCEA BIOSCIENCES, INC. 100 Acorn Park Drive Cambridge, Massachusetts 02149 (617) 876-8191 May 6, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 RE: Genocea Biosciences, Inc. Registration Statement on Form S-3 (File No. 333-255610) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated und |
|
| April 29, 2021 |
Opinion of Ropes & Gray LLP relating to the purchase agreement (filed herewith) Exhibit 5.3 April 29, 2021 Genocea Biosciences, Inc. Cambridge Discovery Park 100 Acorn Park Drive, 5th Floor Cambridge, MA 02140 Re: Registration Statement on Form S-3 Ladies and Gentlemen: This opinion is furnished to you in connection with the registration statement on Form S-3 (the ?Registration Statement?) filed on the date hereof with the Securities and Exchange Commission, the base prospect |
|
| April 29, 2021 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Provides First Quarter 2021 Corporate Update GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens? and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., APRIL 29, 2021 - Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developi |
|
| April 29, 2021 |
As filed with the Securities and Exchange Commission on April 29, 2021 Registration No. |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 GENOCEA BIOSCIENCES, INC. |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 29, 2021 |
Name of Grantee: [] Target Number of PSUs: [] Date of Grant: [] Genocea Biosciences, Inc. |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| April 29, 2021 |
DEFA14A 1 a2021proxynotice.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| April 14, 2021 |
PRE 14A 1 a2021gncaproxyprelim.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| April 14, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842 |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 31, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 22, 2021 |
of the Company's Annual Report on Form 10-K, File No. 001-36289, filed on February 22, 2021) Exhibit 10.7 SUBLEASE This instrument is a Sublease (the ?Sublease?) dated as of November 30, 2020 (the ?Execution Date?) between GENOCEA BIOSCIENCES, INC., a Delaware corporation (?Sublessor?), and ZYMERGEN INC., a Delaware corporation (?Sublessee?). The parties to this instrument hereby agree with each other as follows: Article 1 SUMMARY OF BASIC SUBLEASE PROVISIONS 1.1 BASIC DATA ALL CAPITALIZE |
|
| February 22, 2021 |
As filed with the Securities and Exchange Commission on February 22, 2021 Registration No. |
|
| February 22, 2021 |
Loan and Security Agreement between the Company and Silicon Valley Bank, dated February 18, 2021 Exhibit 10.26 Portions of this exhibit have been redacted because they are both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark [* * *]. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?) dated as of February 18, 2021 (the ?Effecti |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36289 GENOCEA BIOSCIENCES, INC. |
|
| February 22, 2021 |
Exhibit 4.10 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTA |
|
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Genocea Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genocea Biosciences, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 372427401 (CUSIP Number) December 31, 2020 Date of Event Which Requires Filing of the Statement Check the appropriate box |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427401 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 372427401 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| February 12, 2021 |
SC 13G/A 1 gnca-sc13ga021221.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing o |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427401 (CUSIP Number) December |
|
| February 12, 2021 |
SC 13G/A 1 ea135462-13ga2vivoopgenocea.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) December 31, 2020 (Date of Event which Requires |
|
| February 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| February 11, 2021 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Provides Fourth Quarter 2020 Corporate Update GEN-011 and GEN-009 clinical trials continue to advance ATLASTM stimulatory antigen and inhibitory antigen (InhibigenTM) identification profiled in Cancer Discovery Announcing SARS-CoV-2 T cell antigen discovery program Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., |
|
| January 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissi |
|
| January 4, 2021 |
genoceacorporatepresenta Better personalized cancer immunotherapies through better neoantigen targeting January 2021 2 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| November 18, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| November 18, 2020 |
genoceacorporatepresenta Better personalized cancer immunotherapies through better neoantigen targeting November 2020 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| November 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2020 |
sitcinvestorpresentation GEN-009 Part B SITC data presentation November 9, 2020 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| November 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2020 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020 Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies GEN-011, a neoantigen-targeted |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commiss |
|
| October 29, 2020 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Provides Third Quarter 2020 Corporate Update Initiated GEN-011 Phase1/2a clinical trial Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy Closed financing with net proceeds of $74.5 million Upcoming presentations at SITC 2020 Virtu |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| September 22, 2020 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Announces FDA Acceptance of GEN-011 IND Application Novel adoptive T cell therapy targets checkpoint-refractory solid tumors with neoantigen-specific T cells from peripheral blood CAMBRIDGE, Mass., September 22, 2020 – Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantig |
|
| September 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commi |
|
| August 28, 2020 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-248103 PROSPECTUS GENOCEA BIOSCIENCES, INC. 21,390,902 Shares of Common Stock Warrants to Purchase 45,835,978 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to (i) 21,390,902 shares of our common stock, par value $0.001 per share (the “Common Stock”), and (ii) up to 45,835,978 shares of |
|
| August 26, 2020 |
CORRESP 1 filename1.htm GENOCEA BIOSCIENCES, INC. 100 Acorn Park Drive Cambridge, Massachusetts 02149 (617) 876-8191 August 26, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 RE: Genocea Biosciences, Inc. Registration Statement on Form S-3 (File No. 333-248103) Request for Acceleration Ladies and Gentlemen: Pursuant |
|
| August 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 51-0596811 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 100 Acorn Park Drive Cambridge, Massachusetts 02140 (617) 876- |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| August 3, 2020 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842 |
|
| July 31, 2020 |
GNCA / Genocea Biosciences, Inc. / CITADEL ADVISORS LLC - SCHDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427401 (CUSIP Number) July 22, 2020 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ |
|
| July 31, 2020 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Genocea Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| July 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 30, 2020 |
gen-009partbdatajuly2020 GEN-009 Ph1/2a Part B Discussion of Initial Clinical Data July 30, 2020 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| July 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 30, 2020 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Webcast/conference call scheduled today, July 30th at 8:00 a.m. EDT Three of five patients achieved separate RECIST responses after GEN-009 administration GEN-009 elicited antigen-specific CD4+ and CD8+ T cell responses in 100% of treated patients CAMBRIDGE, Mass., July 30, 2020 – Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopha |
|
| July 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| July 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 23, 2020 |
STATE OF DELAWARE CERTIFICATE OF CORRECTION OF GENOCEA BIOSCIENCES, INC. Genocea Biosciences, Inc., a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the corporation is Genocea Biosciences, Inc. SECOND: A Certificate of Amendment to the Restated Certificate of |
|
| July 23, 2020 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Provides Second Quarter 2020 Corporate Update Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDT Filed IND application for GEN-011 and is working with the FDA to provide additional information Private Placement with Leading Life Science Investment Funds Conference call today at 8:30 a.m. EDT CAMBRIDGE, Mass., |
|
| July 22, 2020 |
gncaformofprefundedwarra NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| July 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 22, 2020 |
gncaformofwarrant NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| July 22, 2020 |
gncapurchaseagreement SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 22, 2020 (the “Effective Date”), among Genocea Biosciences, Inc. |
|
| July 20, 2020 |
GENOCEA BIOSCIENCES PROVIDES CLINICAL UPDATE Investor Contact: Dan Ferry 617-430-7576 [email protected] GENOCEA BIOSCIENCES PROVIDES CLINICAL UPDATE CAMBRIDGE, Mass., July 20, 2020 - Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates to its clinical programs, the neoantigen vaccine GEN-009 and the neoantigen cell therapy, GEN-011. GEN-0 |
|
| July 20, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 6, 2020 |
corpdeckjuly2020 Better cancer immunotherapies through better antigen selection July 2020 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| July 6, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| June 19, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| June 19, 2020 |
POWER OF ATTORNEY Know all by those present, that the undersigned hereby constitutes and appoints each of William Clark and Diantha Duvall, signing singly, as the undersignedTMs true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersignedTMs capacity as an officer and/or director of Genocea Biosciences, Inc. |
|
| June 2, 2020 |
Registration No. 333- As filed with the Securities and Exchange Commission on June 2, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 51-0596811 (State or other jurisdiction of incorporation or organization) (IRS Emplo |
|
| June 2, 2020 |
GENOCEA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based Awards. 3. ADMINISTRATI |
|
| June 2, 2020 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF GENOCEA BIOSCIENCES, INC. |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defi |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defi |
|
| May 22, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2020 |
gen011kolsymposium12may2 GEN-011: Transforming T cell therapy for solid tumors KOL Symposium 12 May 2020 GEN-011: Designed to improve upon TIL therapy T cells targeting the right tumor neoantigens Peripheral blood T cells enabling greater activity and durability Robust and rapidly scalable manufacturing process 2 TIL therapy: Current gold standard for solid tumor cell therapy Tumor-infiltrating lymphocyte (TIL) 2,3,4 CAR-T therapy Unproven in solid tumors TCR-transduced (TCR-T) Limited clinical validation HLA-limited Durable efficacy Potential safety concerns1 in checkpoint-refractory patients 1. |
|
| May 12, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| April 30, 2020 |
Exhibit 10.2 September 17, 2018 Dear Tom: This letter agreement (“Agreement”) sets forth the terms and conditions of your offer of employment with Genocea Biosciences, Inc. (the “Company”). If accepted, the terms hereof shall be effective and your employment shall commence on October 1, 2018 (the “Effective Date”). 1.Position and Duties. You shall serve, on a full-time basis, as the Company’s Chie |
|
| April 30, 2020 |
Exhibit 10.3 Name: [] Number of Restricted Stock Units subject to Award: [] Date of Grant: [] GENOCEA BIOSCIENCES, INC. 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units granted by Genocea Biosciences, Inc. (the “Company”) to the individual named above (the “Grantee”), pursuant to and subjec |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| April 30, 2020 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Provides First Quarter 2020 Corporate Update Clinical stage programs GEN-009 and GEN-011 continue to advance Anticipate GEN-011 IND filing in Q2 Expect GEN-009 Phase 1/2a Part B readout in Q3 GEN-011 Virtual Symposium planned for May 12th Conference call today at 8:30 a.m. EDT CAMBRIDGE, Mass., April 30, 2020 - Genocea Bio |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| April 30, 2020 |
Exhibit 10.1 November 6, 2018 Dear Girish: This letter agreement ("Agreement") sets forth the terms and conditions of your offer of employment with Genocea Biosciences, Inc. (the "Company"). If accepted, the terms hereof shall be effective, and your employment shall commence on December 6, 2018 (the "Effective Date"). 1.Position and Duties. You shall serve, on a full-time basis, as the Company's C |
|
| April 20, 2020 |
GNCA / Genocea Biosciences, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| April 20, 2020 |
GNCA / Genocea Biosciences, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 6, 2020 |
GNCA / Genocea Biosciences, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| February 28, 2020 |
SC 13G/A 1 gnca-sc13ga021320.htm AMENDMENT NO. 2 TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427104 (CUSIP Number) February 13, 2020 (Date of Event Which Requires Fi |
|
| February 14, 2020 |
GNCA / Genocea Biosciences, Inc. / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427401 (CUSIP Number) December |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the common stock, par value $0.001 per share, of Genocea Biosciences, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of |
|
| February 13, 2020 |
EXHIBIT 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO GENOCEA BIOSCIENCES, INC. IF PUBLICLY DISCLOSED. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (“Agreement”) is entered into as of this 19th day of November, 2012 (the “Amended and Rest |
|
| February 13, 2020 |
SECOND AMENDMENT OF LEASE THIS SECOND AMENDMENT OF LEASE (this “Amendment”) is made as of the 1st day of May, 2019, by 100 Discovery Park DE, LLC, a Delaware limited liability company (as successor in interest to TBCI, LLC, as Trustee of 100 Discovery Park Realty Trust) (“Landlord”), and Genocea Biosciences, Inc. |
|
| February 13, 2020 |
GNCA / Genocea Biosciences, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36289 GENOCEA BIOSCIENCES, INC. |
|
| February 13, 2020 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Genocea Biosciences Inc. |
|
| February 13, 2020 |
Powers of Attorney (included on the signature page in Part II). Registration No. 333- As filed with the Securities and Exchange Commission on February 13, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 51-0596811 (State or other jurisdiction of incorporation or organization) (IRS |
|
| February 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| February 13, 2020 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Provides Fourth Quarter 2019 Corporate Update ATLASTM identifies Inhibigenstm that can undermine immunotherapy Dosed first patient in Part B of GEN-009 neoantigen vaccine Phase 1/2a trial Progressed GEN-011 neoantigen cell therapy - IND filing expected in Q2 2020 Appointed Dr. Gisela Schwab to Genocea’s Board of Directors |
|
| February 13, 2020 |
GNCA / Genocea Biosciences, Inc. / UBS OCONNOR LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427401 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 13, 2020 |
genoceacorporatepresenta Next generation cancer immunotherapies 1 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commiss |
|
| November 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| November 19, 2019 |
genoceacorporatepresenta Next generation neoantigen immunotherapies | CONFIDENTIAL 1 This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| November 19, 2019 |
FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of November 14, 2019 and is entered into by and between (a) GENOCEA BIOSCIENCES, INC. |
|
| November 8, 2019 |
424B5 1 prospectussupplement1182019.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-225086 PROSPECTUS SUPPLEMENT (To Prospectus dated June 5, 2018) $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC ("Cowen"), relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the |
|
| November 5, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commiss |
|
| November 5, 2019 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC) Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm posit |
|
| October 24, 2019 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-225086 PROSPECTUS SUPPLEMENT (To Prospectus dated June 5, 2018) Up to $30,000,000 of Shares of Common Stock and 289,966 Shares of Common Stock GENOCEA BIOSCIENCES, INC. This prospectus supplement relates to the issuance and sale of up to $30,000,000 in shares of our common stock, and an additional 289,966 shares of common stock as Commitment Sh |
|
| October 24, 2019 |
GNCA / Genocea Biosciences, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| October 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commiss |
|
| October 24, 2019 |
Execution Version PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of October 23, 2019 (the “Execution Date”), is entered into by and between GENOCEA BIOSCIENCES, INC. |
|
| October 24, 2019 |
Investor Contact: Dan Ferry 617-430-7576 [email protected] Genocea Provides Corporate Update and Reports Third Quarter 2019 Financial Results Generated unprecedented 98% GEN-009 immune response frequency with ATLAS™ Continued advancement of GEN-011, expect to file an IND in first half of 2020 Entered into a common stock purchase agreement for up to $30M with Lincoln Park Capital Conferenc |
|
| October 24, 2019 |
Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 23, 2019, is entered into by and between GENOCEA BIOSCIENCES, INC. |
|
| July 25, 2019 |
Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009; Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call today at 8:30 am ET CAMBRIDGE, Mass., July 25, 2019 - Genocea Biosciences, Inc. ( |
|
| July 25, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| July 25, 2019 |
Separation Agreement dated July 22, 2019 between Genocea Biosciences, Inc. and Pamela Carroll July 22, 2019 Pam Carroll Dear Pam: As we have discussed, this letter separation and transition agreement (this “Agreement”) confirms the terms of the remainder of your employment with Genocea Biosciences, Inc. |
|
| July 25, 2019 |
GNCA / Genocea Biosciences, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| June 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| June 21, 2019 |
10,500,000 Shares Common Stock Filed pursuant to Rule 424(b)(4) Registration No. 333-232023 PROSPECTUS 10,500,000 Shares Common Stock We are offering 10,500,000 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Capital Market under the symbol “GNCA”. On June 19, 2019, the last sale price on our common stock was $3.85 per share. We are an “emerging growth company” as that term is used in the J |
|
| June 20, 2019 |
GNCA / Genocea Biosciences, Inc. S-1MEF - - S-1MEF As filed with the Securities and Exchange Commission on June 19, 2019 Registration No. |
|
| June 18, 2019 |
Form of Underwriting Agreement Exhibit 1.1 Genocea Biosciences, Inc. [·] Shares of Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York June [·], 2019 SVB Leerink LLC Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 1 |
|
| June 18, 2019 |
GNCA / Genocea Biosciences, Inc. S-1/A - - S-1/A S-1/A 1 s-1documentxamended.htm S-1/A As filed with the Securities and Exchange Commission on June 18, 2019 Registration No. 333-232023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other ju |
|
| June 18, 2019 |
GNCA / Genocea Biosciences, Inc. CORRESP - - CORRESP 1 filename1.htm SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 11th Floor New York, New York 10019 June 18, 2019 Via EDGAR Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, DC 20549-7010 Attn: Ada D. Sarmento Re: Genocea Biosciences, Inc. Regist |
|
| June 17, 2019 |
GNCA / Genocea Biosciences, Inc. CORRESP - - CORRESP 1 filename1.htm June 17, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento Re: Genocea Biosciences, Inc. Registration Statement on Form S-1 (File No. 333-232023) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Genocea Biosciences, Inc., a Delaware corp |
|
| June 7, 2019 |
GNCA / Genocea Biosciences, Inc. S-1 - Registration Statement - S-1 As filed with the Securities and Exchange Commission on June 7, 2019 Registration No. |
|
| June 3, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| June 3, 2019 |
a20190603gncapr Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea’s GEN-009 Vaccine Demonstrates Best-in-Class Immune Responses to ATLAS™-selected Neoantigens in Cancer Patients Post-vaccination T cell responses detected to 91% of vaccine neoantigens, including CD8+ T cell responses to 53% of vaccine neoantigens Conference call and webcast to discuss results TODAY at 8:30 am |
|
| May 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| May 21, 2019 |
degenoceaamendment Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “GENOCEA BIOSCIENCES, INC.”, FILED IN THIS OFFICE ON THE TWENTIETH DAY OF MAY, A.D. 2019, AT 4:54 O`CLOCK P.M. AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERT |
|
| May 16, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2019 |
Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial Post-vaccination immune responses detected to 93% of vaccine neoantigens in first three patients analyzed Additional data to be presented June 1st at ASCO 2019 and discussed on a conference call and webcast on June 3rd CAMB |
|
| May 14, 2019 |
Filed pursuant to Rule 424(b)(3) Registration Statement 333-230577 PROSPECTUS GENOCEA BIOSCIENCES, INC. |
|
| May 10, 2019 |
GNCA / Genocea Biosciences, Inc. CORRESP - - GENOCEA BIOSCIENCES, INC. 100 Acorn Park Drive Cambridge, Massachusetts 02140 (617) 876-8191 May 10, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 RE: Genocea Biosciences, Inc. Registration Statement on Form S-3 (File No. 333-230577) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated un |
|
| April 30, 2019 |
GNCA / Genocea Biosciences, Inc. S-3/A S-3/A S-3/A 1 s-3document1.htm S-3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 51-0596811 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 100 Acorn Pa |
|
| April 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| April 30, 2019 |
Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea Provides Corporate Update, Including First-Quarter 2019 Financial Results Company anticipates presenting first GEN-009 immunogenicity data at ASCO 2019 Conference call today at 9:00 am ET CAMBRIDGE, Mass., April 30, 2019 - Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immu |
|
| April 30, 2019 |
a1subscriptionagreemente SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is dated as of February 11, 2019 (the “Effective Date”), among Genocea Biosciences, Inc. |
|
| April 30, 2019 |
GNCA / Genocea Biosciences, Inc. CORRESP - - ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM April 30, 2019 Marc Rubenstein 617-951-7826 617-413-2944 fax [email protected] BY FEDEX AND EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joseph McCann, Staff Attorney Re: Genocea Biosciences, Inc. Registration Sta |
|
| April 30, 2019 |
GNCA / Genocea Biosciences, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| March 29, 2019 |
GNCA / Genocea Biosciences, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 29, 2019 |
GNCA / Genocea Biosciences, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| March 28, 2019 |
Power of Attorney (previously filed) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 51-0596811 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 100 Acorn Park Drive Cambridge, Massachusetts 02140 (617) 876- |
|
| March 7, 2019 |
GNCA / Genocea Biosciences, Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 4, 2019 |
Powers of Attorney (included on the signature page in Part II). Registration No. 333- As filed with the Securities and Exchange Commission on March 4, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 51-0596811 (State or other jurisdiction of incorporation or organization) (IRS Empl |
|
| February 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| February 28, 2019 |
exhibit991gncaq4resultsp Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea Reports Fourth Quarter 2018 Results and Announces Hiring of New Chief Financial Officer Company advancing lead clinical-stage neoantigen cancer vaccine candidate and expanding pipeline into adoptive cell therapy Diantha Duvall to join as CFO, bringing broad life science financial leadership experience |
|
| February 28, 2019 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 28, 2019 |
GNCA / Genocea Biosciences, Inc. 10-K (Annual Report) 10-K 1 gnca-20181231x10k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| February 28, 2019 |
Exhibit 10.30 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of January 22, 2018 (the “Second Amendment Date”) is entered into by and among GENOCEA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), HERCULES CAPITAL, INC., a Maryland corporation (“HC”), in its capacity as administrative agent for itself and L |
|
| February 25, 2019 |
GNCA / Genocea Biosciences, Inc. / GLAXOSMITHKLINE PLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 372427104 (CUSIP Number) February 14, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| February 14, 2019 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.A CUSIP No. 372427104 Page 1 2 of 13 Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on be |
|
| February 14, 2019 |
GNCA / Genocea Biosciences, Inc. / Polaris Venture Partners V, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 372427104 (CUSIP Number) Polaris Partners One Marina Park Drive, 10th Floor Boston, MA 02210 Attn: Max Eisenberg (855) 787-3500 Gunderson De |
|
| February 14, 2019 |
SC 13G/A 1 sc13ga107422gen02142019.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Genocea Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 |
|
| February 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commis |
|
| February 12, 2019 |
Genocea Announces Private Placement Financing of Up to $39 Million Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea Announces Private Placement Financing of Up to $39 Million CAMBRIDGE, Mass., February 12, 2019 - Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement with certain existing and new investors providing fo |
|
| February 12, 2019 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| February 12, 2019 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| January 7, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 01/07/2019 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 7, 2019 |
genoceajanuary2019 Beyond Machines for Antigen Selection: Using ATLAS™ to Enable Novel Cancer Immunotherapies January 2019 Disclaimer This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| December 13, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 12/13/2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 11/1/2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 1, 2018 |
Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea Reports Third Quarter 2018 Financial and Operating Results Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patients Presenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET CAMBRIDGE, Mass., November 1, 2018 – Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical |
|
| November 1, 2018 |
GNCA / Genocea Biosciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| October 2, 2018 |
exhibit99110118 P R E S S R E L E A S E S G E N O C E A S T R E N G T H E N S L E A D E R S H I P T E A M : T H O M A S D A V I S , M . D . A P P O I N T E D C H I E F M E D I C A L O F F I C E R ; D E R E K M E I S N E R , J . D . J O I N S A S G E N E R A L C O U N S E L October 1, 2018 at 7:30 AM EDT CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) - Genocea Biosc |
|
| October 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 10/1/2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 9/20/2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 24, 2018 |
Genocea Biosciences, Inc. Code of Business Conduct and Ethics, September 2018 finalcodeofbusinessethic Genocea Biosciences, Inc. Code of Business Conduct and Ethics I. INTRODUCTION This Code of Business Conduct and Ethics (“Code”) provides a general statement of the expectations of Genocea Biosciences, Inc. (“Genocea”, or the “Company”) regarding the ethical standards that each director, officer and employee should adhere to while acting on behalf of Genocea. You are expect |
|
| August 7, 2018 |
Narinderjeet Singh Inducement Stock Option Agreement (filed herewith). narindersinghinducementa |
|
| August 7, 2018 |
2014 Employee Stock Purchase Plan, as amended Registration No. 333- As filed with the Securities and Exchange Commission on August 7, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 51-0596811 (State or other jurisdiction of incorporation or organization) (IRS Emp |
|
| August 3, 2018 |
GNCA / Genocea Biosciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36289 Genocea Biosciences, Inc. |
|
| August 3, 2018 |
Exhibit 10.4 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT is made and dated as of April 24, 2018 and is entered into by and between GENOCEA |
|
| August 2, 2018 |
Exhibit 99.1 Contact: Jennifer LaVin 617-715-6687 [email protected] Genocea Reports Second Quarter 2018 Financial and Operating Results Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial underway ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification Conference call today at 9:00 am ET CAMBRIDGE, Mass., August 2, 2018 – Genocea Biosciences, |
|
| August 2, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 8/2/18 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 25, 2018 |
GENOCEA BIOSCIENCES, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED Section 1. Defined Terms Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. Section 2. Purpose of Plan The Plan is intended to enable Eligible Employees of the Company and its Designated Subsidiaries to use payroll deductions to pur |
|
| June 25, 2018 |
CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF GENOCEA BIOSCIENCES, INC. |
|
| June 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2018 GENOCEA BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36289 (Commission File Numbe |
|
| June 25, 2018 |
GENOCEA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN 1.DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based Awards. 3. ADMINISTRATIO |
|
| June 21, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 gnca8kx6x21x18.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2018 GENOCEA BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001 |
|
| June 8, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commission |
|
| June 8, 2018 |
gncacorppresentation6818 Pioneering Neoantigen Vaccines JUNE 2018 Disclaimer This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. |
|
| June 4, 2018 |
GNCA / Genocea Biosciences, Inc. CORRESP CORRESP 1 filename1.htm Genocea Biosciences, Inc. 100 Acorn Park Drive Cambridge, MA 02140 June 4, 2018 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Genocea Biosciences, Inc. Registration Statement on Form S-3 (File No. 333-225086) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securi |
|
| May 21, 2018 |
Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS The following table reflects the computation of the ratio of combined fixed charges and preferred stock dividends to earnings for the periods presented (in thousands): Three Months Ended March 31, 2018 Year Ended December 31, 2017 2016 2015 2014 2013 Net loss $ (10,591 ) $ (56, |
|
| May 21, 2018 |
GNCA / Genocea Biosciences, Inc. S-3 S-3 1 gncas-3.htm S-3 As filed with the Securities and Exchange Commission on May 21, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 51-0596811 (I.R.S E |
|
| May 11, 2018 |
GNCA / Genocea Biosciences, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36289 NOTIFICATION OF LATE FILING CUSIP NUMBER 372427104 (Check one) ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transit |
|
| May 10, 2018 |
GNCA / Genocea Biosciences, Inc. 10-Q (Quarterly Report) 10-Q 1 gnca-20180331x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 10, 2018 |
Exhibit 99.1 For media: Jennifer LaVin 617-715-6687 [email protected] Genocea Reports First Quarter 2018 Financial and Operating Results - Company files IND for lead neoantigen vaccine program, GEN-009 - - ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification - - Conference call today at 9 am ET - CAMBRIDGE, Mass., May 10, 2018 - Genocea Biosciences, |
|
| May 10, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K/A 1 gnca331188ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdicti |
|
| May 10, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 gnca331188k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 5/9/2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incor |
|
| May 10, 2018 |
Exhibit 99.1 For media: Jennifer LaVin 617-715-6687 [email protected] Genocea Reports First Quarter 2018 Financial and Operating Results - Company files IND for lead neoantigen vaccine program, GEN-009 - - ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification - - Conference call today at 9 am ET - CAMBRIDGE, Mass., May 10, 2018 - Genocea Biosciences, |
|
| April 30, 2018 |
AMENDMENT TO EQUITY RIGHTS LETTER AGREEMENT THIS AMENDMENT TO EQUITY RIGHTS LETTER AGREEMENT (this “Amendment”) is made effective as of April 24, 2018 by and between Hercules Capital, Inc. |
|
| April 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2018 GENOCEA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36289 51-0596811 (State or other jurisdiction of incorporation) (Commissio |
|
| April 30, 2018 |
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. |
|
| April 24, 2018 |
GNCA / Genocea Biosciences, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 24, 2018 |
GNCA / Genocea Biosciences, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
